Browsing Tag
ZIIHERA
3 posts
Zymeworks (ZYME) to buy Theravance (TBPH) for $929m in cash plus ampreloxetine CVR
Zymeworks (ZYME) to acquire Theravance (TBPH) for $17/share plus CVR, $929M equity value. Non-recourse OMERS financing minimises ZYME's cash at risk.
Jazz Pharmaceuticals (JAZZ) builds $4bn oncology option through AbCellera partnership
Jazz could pay AbCellera more than $4 billion across five oncology programmes. Read how the option deal reshapes JAZZ and ABCL growth strategies.
BeOne Medicines wins FDA Priority Review for TEVIMBRA in HER2-positive GEA as ONC stock faces trial-to-approval test
BeOne has survival data and FDA momentum. The bigger question is whether TEVIMBRA can change first-line HER2-positive GEA care.